Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY01616 in Advanced Solid Tumors
NCT05865925Phase 2Enrolling by invitation
- Sponsor
- Luye Pharma Group
- Start
- Apr 2021
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of OssiPatch in solid tumor (advanced stage) (6 arms), sponsored by Luye Pharma Group. Primary endpoint: Incidence and severity of adverse events up to 2 years. Started Apr 2021; status: enrolling by invitation.
02
Drugs
OssiPatch
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05865925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05865925.